Document is current
Any future updates will be listed below
-
Authors
Chan, Jack D. https://orcid.org/0000-0002-5942-8592
Scheffler, Christina M. https://orcid.org/0000-0003-3731-6204
Munoz, Isabelle https://orcid.org/0000-0001-6510-5696
Sek, Kevin https://orcid.org/0000-0003-4634-7600
Lee, Joel N.
Huang, Yu-Kuan https://orcid.org/0000-0003-2262-7069
Yap, Kah Min https://orcid.org/0000-0001-5009-9895
Saw, Nicole Y. L.
Li, Jasmine
Chen, Amanda X. Y.
Chan, Cheok Weng
Derrick, Emily B. https://orcid.org/0000-0001-7191-3948
Todd, Kirsten L. https://orcid.org/0000-0002-3903-166X
Tong, Junming https://orcid.org/0009-0006-6454-8704
Dunbar, Phoebe A.
Li, Jiawen
Hoang, Thang X.
de Menezes, Maria N. https://orcid.org/0000-0003-3231-0620
Petley, Emma V.
Kim, Joelle S.
Nguyen, Dat
Leung, Patrick S. K.
So, Joan https://orcid.org/0000-0001-6550-0637
Deguit, Christian https://orcid.org/0000-0003-0759-4035
Zhu, Joe https://orcid.org/0000-0003-4416-7040
House, Imran G. https://orcid.org/0000-0002-6245-5954
Kats, Lev M. https://orcid.org/0000-0001-8742-8138
Scott, Andrew M.
Solomon, Benjamin J. https://orcid.org/0000-0003-3059-5730
Harrison, Simon J. https://orcid.org/0000-0003-4555-6582
Oliaro, Jane https://orcid.org/0000-0002-2097-6428
Parish, Ian A. https://orcid.org/0000-0003-3528-478X
Quinn, Kylie M. https://orcid.org/0000-0002-0417-3625
Neeson, Paul J. https://orcid.org/0000-0002-2729-5887
Slaney, Clare Y.
Lai, Junyun https://orcid.org/0000-0001-5884-2786
Beavis, Paul A. https://orcid.org/0000-0002-2116-013X
Darcy, Phillip K. https://orcid.org/0000-0002-5303-9561
- License Information
-
More Information
Article History
Received: 13 February 2023
Accepted: 27 February 2024
First Online: 10 April 2024
Competing interests
: P.A.B. declares research funding from AstraZeneca, Bristol-Myers-Squibb and Gilead Sciences. P.K.D. declares research funding from Myeloid Therapeutics, Prescient Therapeutics, Bristol-Myers-Squibb and Juno Therapeutics. J. Lai is a present employee at oNKo-Innate. S.J.H. declares consultancy fees and honoraria from Celgene, Janssen Cilag and Novartis; declares research funding from Celgene, Janssen Cilag, Novartis and Haemalogix; was an investigator on studies for Celgene, Janssen Cilag, Novartis and Haemalogix; and has served on the advisory board for Celgene, Janssen Cilag, Novartis and Haemalogix. I.A.P. declares research funding from Bristol-Myers-Squibb and Astrazeneca. The other authors declare no competing interests.
